Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Jiang, MA
Aiping Jiang, Lexington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090143672 | METHOD FOR MAPPING IMAGE REFERENCE POINTS TO FACILITATE BIOPSY USING MAGNETIC RESONANCE IMAGING - In NMR/MRI imaging, a location is noted for a point in the imaged space, and referred to a reference location so that the point in imaged space is known thereafter, without the need to locate the point again in further imaging steps. For breast cancer diagnosis and biopsy, a breast holding fixture immobilizes the breast. A volumetric image is taken encompassing a portion of the breast. In the same or a subsequent image, a fiducial mark is detected to determine the position of a holder for a biopsy tool or other modality. The tissue feature can be a tumor, cyst or tubal lesion, made temporarily visible in the image by perfusion with a contrast agent. After the contrast agent dissipates, the location of the tissue feature can still be determined by reference to the position of the fiducial marker, which is optional adjustable by post-imaging metered displacement. | 06-04-2009 |
| 20100145185 | EXTENDING THE RESOLUTION OF MRI DATA BY COMBINING SUBSETS FROM PLURAL IMAGE ACQUISITIONS - An MRI image from spiral trajectory scanning is arranged as complementary subsets of values in time-sampled k-space. These values are Fourier transformed to produce a spatial domain image. While holding the patient stationary, the contrast information is updated at the central portion of k-space, and the peripheral portion of k-space data can be filled during the whole image acquisition. The contrast information is combined with the peripheral portion of k-space (contributing to image resolution) to construct a full k-space data and to generate a spatial image. The technique is useful for providing short time interval sampling when analyzing the take-up and fade-away of a contrast agent over time. | 06-10-2010 |
Bianca X. Jiang, Lexington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120005667 | INTEGRATED EXCHANGE OF DEVELOPMENT TOOL CONSOLE DATA - Embodiments of the present invention provide a method, system and computer program product for exchanging console data in a messaging system. In an embodiment of the invention, a method for exchanging console data in a messaging system includes receiving a message in a messaging client executing in memory by at least one processor of a computer. The method further includes selecting in the message in the messaging client a portion of console data for a version of source code. For instance, the console data can be a selection of source code or an error message for a selection of source code. Finally, in response to the selection of the portion of console data, corresponding meta-data for the message can be extracted and a version of source code for the console data can be determined from the meta-data. Finally, the version of the source code can be loaded in an IDE executing in the memory by the at least one processor of the computer. | 01-05-2012 |
Canwen Jiang, Southborough, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090105125 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 04-23-2009 |
| 20100047225 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. | 02-25-2010 |
Chunsheng Jiang, Reading, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110110567 | Methods and Apparatus for Visually Enhancing Images - The invention provides methods of enhancing tissue sample images by filtering luminance values from an input image and transforming the filtered values to produce an enhanced image for use in diagnostic applications. Preferred methods of the invention provide image enhancement by filtering luminance values of an image that correspond to sample regions that are obstructed or are otherwise not of diagnostic interest, and applying a mathematical transformation based on luminance values from regions that are not filtered out. In this way, image correction is substantially based on portions of the image that are of diagnostic relevance. | 05-12-2011 |
| 20110144462 | MINIATURIZED MULTI-SPECTRAL IMAGER FOR REAL-TIME TISSUE OXYGENATION MEASUREMENT - A portable multi-spectral imaging system and device is disclosed. The system includes at least one image acquisition device for acquiring an image from a subject, a filtering device to filter the light received by the image acquisition device, a processor for processing the image acquired by the image acquisition device, and a display. There is software running on the processor that determines oxygenation values of the subject based on the processed image. | 06-16-2011 |
Feng Jiang, Natick, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120231478 | TIVOZANIB RESPONSE PREDICTION - A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry. | 09-13-2012 |
| 20120252829 | TIVOZANIB AND CAPECITABINE COMBINATION THERAPY - A method of treating a tumor in a subject using a combination of tivozanib and capecitabine is disclosed. | 10-04-2012 |
Haiyan Jiang, Belmont, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120027743 | Method for the Treatment of Hemophilia - The present invention is directed to a method for the treatment of hemophilia. | 02-02-2012 |
| 20130017997 | Factor VIII Compositions and Methods of Making and Using Same - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 01-17-2013 |
Hua David Jiang, Boston, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100163334 | SOUND MAXIMIZING AMMELLESCOPE - In this device, three chambers, three chips with multiple holes and three membranes senses and magnifies sound signal from miles away to a magnitude that can be heard by device holder. Sound wave enter from the membrane, vibration energy is transmitted by highly compressed air within chamber | 07-01-2010 |
James Zhiming Jiang, Burlington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20130030543 | HIP IMPLANT - Provided herein are hip implant devices and related surgical methods. The hip implants and methods can optionally be used in patients of Asian descent. | 01-31-2013 |
Jiaoyang Jiang, Boston, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110250604 | METHODS OF DETECTING SOURCES OF MICROORGANISM CONTAMINATION - Methods of detecting a source of a microbial contamination in a suspect sample include detecting at least one member selected from the group consisting of a microbial geosmin synthase, a microbial 2-methylisoborneol synthase and a microbial 2-methylgeranyl diphosphate synthase in the suspect sample. The method can include conducting a nucleic acid amplification assay in the presence of at least one member selected from the group consisting of at least one microbial geosmin primer and at least one microbial 2-methylisoborneol synthase primer on a sample obtained from a suspect source of the microbial contamination. | 10-13-2011 |
Jinwei Jiang, Chestnut Hill, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120027773 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 02-02-2012 |
Jun Jiang, Acton, MA US
Kai Jiang, Malden, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120104990 | Alkali Metal Ion Battery with Bimetallic Electrode - Electrochemical cells having molten electrodes having an alkali metal provide receipt and delivery of power by transporting atoms of the alkali metal between electrode environments of disparate chemical potentials through an electrochemical pathway comprising a salt of the alkali metal. The chemical potential of the alkali metal is decreased when combined with one or more non-alkali metals, thus producing a voltage between an electrode comprising the molten the alkali metal and the electrode comprising the combined alkali/non-alkali metals. | 05-03-2012 |
Leaf A. Jiang, Arlington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090087186 | TIME-MULTIPLEXED OPTICAL WAVEFORM GENERATION - A time-multiplexed waveform generator includes a wavelength splitter that receives an input optical signal and spectrally separates the input optical signal into a plurality of frequency components. A plurality of intensity modulators receives each of the frequency components and passes each of the frequency components for a selective time period, and then extinguishes that frequency for the remainder of a chirp time, the plurality of intensity modulators producing a plurality of first output signals. A plurality of adjustable delay lines is positioned after the intensity modulators and receives the first output signals. Each of the adjustable delay lines enables phase control of each of the frequency components associated with the first output signals for compensating any relative drifts of the path lengths and phase coherently stitching a plurality of sub-chirps together. The adjustable delay lines produce a plurality of second output signals. A wavelength combiner receives the second output signals and recombines the output signals to produce a stair-step waveform output signal. | 04-02-2009 |
Lijuan Jiang, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110217261 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION - The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity. | 09-08-2011 |
Min Jiang, Lexington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-05-2012 |
Min Jiang, Acton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090190615 | HIGH POWER PULSED FIBER LASER - A high power fiber laser includes a pump source optically coupled to a first fiber laser, which is in turn optically coupled to a second fiber laser. The pump source is adapted to generate light, which is received by the first fiber laser and used to generate a first pulsed output. The first pulsed output is directed into the second fiber laser and is used to generate a second pulsed output. The first fiber laser includes a multi-mode fiber, while the second fiber laser includes a single mode fiber. | 07-30-2009 |
| 20100226395 | GAIN-SWITCHED FIBER LASER SYSTEM - This invention discloses a method to control laser dynamics in a gain-switched fiber laser so as to generate stable, clean pulses in an all-fiber format. The gain-switched fiber laser is suitable as a standalone laser source, and as a pump source for harmonic generation and an optical-parametric-oscillator. | 09-09-2010 |
Peng Jiang, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20130039618 | PATTERNED NON-RECIPROCAL OPTICAL RESONATOR - A patterned nonreciprocal optical resonator structure is provided that includes a resonator structure that receives an optical signal. A top cladding layer is deposited on a selective portion of the resonator structure. The top cladding layer is patterned so as to expose the core of the resonator structure defined by the selective portion. A magneto-optically active layer includes a magneto-optical medium being deposited on the exposed core of the resonator structure so as to generate optical non-reciprocity. | 02-14-2013 |
Qingping Jiang, East Walpole, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080305557 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus. | 12-11-2008 |
| 20090029349 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus. | 01-29-2009 |
| 20090318627 | SOLID PHASE SYNTHESIS OF ACRIDINIUM DERIVATIVES - Acridinium-functionalized solid-phase supports and methods for making acridinium-functionalized solid-phase supports are disclosed. The acridinium-functionalized solid-phase supports comprise a solid phase support linked to a chemiluminescent substituted acridinium compound through a linker group covalently attached to the nitrogen atom of the acridinium nucleus and the solid phase support as exemplified in FIG. | 12-24-2009 |
| 20100099077 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION - Chemiluminescent acridinium esters are provided which are fast light emitting and hydrolytically stable. The chemiluminescent acridinium esters are useful labels in assays for detecting or quantifying analytes. | 04-22-2010 |
| 20120225497 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS - Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity. | 09-06-2012 |
Sheng Jiang, Chicopee, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100081764 | AQUEOUS POLYMER DISPERSION AND PROCESS - There is described a multi step process for preparing an aqueous dispersion of heterogeneous polymer particles by mini-emulsion polymerisation, the process comprising the steps of (I) (a) forming a mixture comprising: (i) water; (ii) at least one stabiliser (such as a surfactant and a hydrophobic co-stabiliser); (iii) at least one tackifier (such as polyterpenes, rosin resins and/or hydrocarbon resins); (iv) at least one α,β-ethylenically unsaturated monomer; (b) applying high shear to the mixture from step (a) to form an essentially stable mini-emulsion comprising an aqueous continuous phase and dispersed therein stabilised droplets of average diameter from about 10 to about 1000 nm, (c) polymerising the monomer(s) within the droplets in the presence of a free radical initiator; (d) adding further monomer to the dispersed phase to form a dispersion; then: (II) using the dispersion from step (I) as a seed to form a dispersion of heterogeneous polymer particles in a subsequent emulsion polymerisation. The resultant tackified PSAs may have a core shell structure and are stable under high shear. | 04-01-2010 |
| 20100093930 | Polymer Composition and Process - There is described a multi step mini-emulsion process for preparing a hybrid acrylic/polyurethane pressure sensitive adhesive (PSA) of very high shear strength, good peel strength and/or also high moisture vapor transmission rate, the process comprising the steps of: a) forming a first aqueous mixture comprising a hydrophilic stabilizer; b) forming separately a second oil mixture comprising: i) at least one vinyl functional polyurethane (optionally prepared from an isocyanate functional monomer; at least one monol and/or at least one α,β-ethylenically unsaturated monomer ii) optionally at least one hydrocarbon polymer (such as polystyrene); and iii) at least one α,β-ethylenically unsaturated monomer (such as (meth)acrylate or acids thereof; and/or iv) option-=ally at least one hydrophobic stabilizer; where components (ii), (iii) and/or (iv) may optionally be the same; c) mixing the aqueous and oil mixtures together to form a pre-(macro) emulsion; d) generating a stable mini-emulsion there-from optionally by applying high shear to form an aqueous continuous phase and stabilized oil droplets of average diameter from about 10 to about 1000 nm, and e) polymerizing the polymer precursor(s) within the droplets, optionally in the presence of a free radical initiator; to obtain a polymer latex. | 04-15-2010 |
Shisong Jiang, Chestnut Hill, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120082643 | Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response - The present invention provides compositions and methods for the treatment and prevention of immune disorders. | 04-05-2012 |
Tieying Jiang, Shrewsbury, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110142379 | THREE-DIMENSIONAL PLASTIC BAG AND PRODUCTION THEREOF - The present invention relates to an insert for reinforcement of bags made of plastic film, comprising a star-like plastic part having at least three jaws, wherein the insert is adapted for insertion and heat-sealing at a junction inside a three-dimensional bag where at least three plastic films meet, so that each jaw extends in a direction between two films. The invention also relates to a three dimensional bag incorporating such inserts and a method of producing such a bag. | 06-16-2011 |
| 20110151551 | BIOREACTORS - The present invention relates to improved single-use bioreactors comprising disposable plastic bags for cell cultivation. The invention provides an inflatable bioreactor bag for cell cultivation comprised of a top and a bottom sheet of polymer material that are joined along their edges to form a sealed bag, wherein two opposing edges are formed as clamping edges to allow clamping of the bioreactor bag to a rocker type bioreactor, and wherein the bioreactor bag is provided with a wrinkle preventing structure at each end of the clamping edges. The bag avoids formation of undesired wrinkles or creases which otherwise lead to fatigue of the plastic and eventually fracture. | 06-23-2011 |
| 20110151552 | BIOREACTORS - The present invention relates to improvements of bioreactor bags for cell cultivation. The invention provides an inflatable bioreactor bag for cell cultivation comprised of a top and a bottom sheet of polymer material that are joined along their edges to form a sealed bag, wherein two opposing edges are formed as clamping edges to allow clamping of the bioreactor bag to a rocker type bioreactor, wherein the top sheet is at least 5% longer than the bottom sheet between the clamping edges. The bioreactor bags provided by the invention avoid formation of undesired wrinkles or creases which otherwise may lead to fatigue of the plastic and eventually fracture. | 06-23-2011 |
Tongbo Jiang, Bedford, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110114833 | System and Method for Diversion of a Liquid Chromatography Eluant - In accordance with an embodiment of the invention, there is provided a method for reducing or eliminating matrix interfering components in a biopharmaceutical product in a liquid chromatography-mass spectrometry system. The method comprises diverting to waste the entire flow of an eluant emerging from liquid chromatography of a sample, for a time period to remove contaminants that cause matrix interference to a degree sufficient to allow a desired accuracy in detection of an extractable; and, after the time period, directing the entire flow of the eluant to a mass spectrometer to detect the presence of the extractable. | 05-19-2011 |
| 20110278446 | Method of Detecting Filter Extractables in Biopharmaceutical Products By Liquid Chromatography-Mass Spectrometry. - The invention uses liquid chromatography-mass spectrometry to verify the presence or absence of the extractables introduced into a biopharmaceutical product during manufacture, filtration or storage at above a certain concentration. The method disclosed herein can be used to detect the presence of extractables in the actual biopharmaceutical product rather than a surrogate solvent system. Detection of the extractables in the actual drug product provides an accurate description of the leachables profile likely to be introduced to the human or animal patient. In one embodiment, the extractable are introduced by filtration of the bio-pharmaceutical product. | 11-17-2011 |
Xiaocheng Jiang, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110042641 | BRANCHED NANOSCALE WIRES - The present invention generally relates to nanotechnology and, in particular, to branched nanoscale wires cases, the branched nanoscale wires may be produced using vapor-phase and/or solution-phase synthesis. Branched nanoscale wires may be grown by depositing nanoparticles onto a nanoscale wire, and segments or “branches” can then be grown from the nanoparticles. The nanoscale wire may be any nanoscale wire, for example, a semiconductor nanoscale wire, a nanoscale wire having a core and a shell. The segments may be of the same, or of different materials, than the nanoscale wire, for example, semiconductor/metal, semiconductor/semiconductor. The junction between the segment and the nanoscale wire, in some cases, is epitaxial. In one embodiment, the nanoparticles are adsorbed onto the nanoscale wire by immobilizing a positively-charged entity, such as polylysine, to the nanoscale wire, and exposing it to the nanoparticles. In another embodiment, nanoparticles are deposited onto a nanoscale wire by etching the nanoscale wire to produce an H-terminated surface, then exposing the surface to a solution comprising a metal ion, which be reduced by the surface to form nanoparticles. Segments or branches can then be grown from the deposited nanoparticles to the branched nanoscale wire. | 02-24-2011 |
Xiaoqian Jiang, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110137829 | Method for Selecting Neighborhoods of Training Points for Local Learning - A method selects a subset of training points near a query point from a set of training points. The subset of training points near the query point is determined from a the set of training points such that a cumulative similarity is maximized, wherein the cumulative similarity measures a similarity of the query point to each point in the subset and a similarity of points in the subset to each other. | 06-09-2011 |
| 20110160927 | Method for Prediction for Nonlinear Seasonal Time Series - A method predicts nonlinear seasonal time series data. More particularly, the method predicts short term power demand. The method uses an exponential smoothing technique and dynamic modeling of seasonal time series data with kernels. The kernels are used to predict future values of the time series from past values using nonlinear functions such as a least-squares radial basis function or support vector regression using a Gaussian kernel. | 06-30-2011 |
Xinli Jiang, Shrewsbury, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100067858 | Bandwidth-maintaining multimode optical fibers - The specification describes multimode optical fibers with specific design parameters, i.e., controlled refractive index design ratios and dimensions, which render the optical fibers largely immune to moderately severe bends. The modal structure in the optical fibers is also largely unaffected by bending, thus leaving the optical fiber bandwidth essentially unimpaired. Bend performance results were established by DMD measurements of fibers wound on mandrels vs. measurements of fibers with no severe bends. | 03-18-2010 |
| 20110243519 | OPTICAL FIBERS WITH TRUNCATED CORES - Optical fiber designs are depicted with a core having an alpha profile inner portion and a steep vertical step between the core and a cladding with no shoulder, referred to herein as a truncated core. A further aspect of this invention can include a trench between the truncated core and cladding. In this embodiment, the core performs as not only as the primary light guiding structure, but now also functions essentially the same as that of a trench structure. Thus, what was formally a trench can now be much less negative or even positive. | 10-06-2011 |
| 20120183267 | BANDWIDTH-MAINTAINING MULTIMODE OPTICAL FIBERS - The specification describes multimode optical fibers with specific design parameters, i.e., controlled refractive index design ratios and dimensions, which render the optical fibers largely immune to moderately severe bends. The modal structure in the optical fibers is also largely unaffected by bending, thus leaving the optical fiber bandwidth essentially unimpaired. Bend performance results were established by DMD measurements of fibers wound on mandrels vs. measurements of fibers with no severe bends. Additional embodiments of the present invention describe an improved optical link when the inventive multimode fiber is connected to standard or conventional multimode fibers. | 07-19-2012 |
Xinli Jiang, Shrewsbruy, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110194827 | DMD PERFORMANCE IN BEND OPTIMIZED MULTIMODE FIBER - Optical fiber refractive index profile designs having an alpha core profile and a negative index trench to control bend loss, are modified by truncating the edge of the alpha core profile and adding a ledge to the truncated core. The result is low bend loss and preservation of low differential mode delay and high bandwidth. | 08-11-2011 |
Xuliang Jiang, Braintree, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080280832 | Novel Fsh Glycosylation Variant D3n - FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described. | 11-13-2008 |
| 20090018070 | Fsh Mutants - FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described. | 01-15-2009 |
| 20090093462 | 3-Arylamino pyridine derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. | 04-09-2009 |
| 20090130712 | Compositions and Methods of Producing Hybrid Antigen Binding Molecules and Uses Thereof - This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy. | 05-21-2009 |
| 20090306069 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES - The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. | 12-10-2009 |
| 20110224192 | 3-Arylamino Pyridine Derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds | 09-15-2011 |
| 20110294801 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS - Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed kinase activity such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases. | 12-01-2011 |
| 20120295889 | 3-Arylamino Pyridine Derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds | 11-22-2012 |
Yandong Jiang, North Reading, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080216843 | METHODS AND DEVICES FOR RELIEVING UPPER AIRWAY OBSTRUCTIONS - Methods and devices are provided that are effective to remove an obstruction in a human airway related to snoring and/or OSA. In one embodiment, the device includes mouthpiece having a hollow body configured to be disposed in a user's mouth. The body includes superior and inferior outer surfaces as well as anterior and posterior surfaces, a channel configured to receive a user's teeth formed in at least one of the superior and inferior surfaces, an inner cavity formed between the superior, inferior, anterior, and posterior surfaces, and at least one aperture formed in the posterior surface that extends into the inner cavity. In one exemplary embodiment the at least one aperture is oriented to extend away from the user's teeth and toward a user's tongue when the mouthpiece is in use. In another embodiment, the hollow body is substantially c-shaped, and the at least one aperture includes a plurality of apertures spaced a distance apart from one another along the posterior surface between first and second terminal ends of the c-shaped inner portion of the hollow body. In still another embodiment, the mouthpiece includes an outer portion having an opening extending therethrough such that the outer portion is coupled to the hollow body and is in fluid communication with the cavity in the hollow body. A one-way valve can be disposed in the opening and can be configured to allow air to flow out of a user's oral cavity when the mouthpiece is in use. | 09-11-2008 |
| 20100106037 | METHOD AND DEVICE FOR DETERMINING CARDIAC OUTPUT WITH CARBON DIOXIDE PARTIAL RE-BREATHING - A method and apparatus ( | 04-29-2010 |
Yanjie Jiang, Acton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090263347 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues. | 10-22-2009 |
| 20100331266 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 12-30-2010 |
Yivan Jiang, Stow, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100151037 | METHOD FOR THE PREPARATION OF NANOPARTICLES CONTAINING A POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE COMPOUND - The present application relates to a method for preparing nanoparticles containing a poorly water-soluble pharmaceutically acceptable compound and compositions containing such nanoparticulates. | 06-17-2010 |
Zhiping Jiang, Westfield, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090023054 | Lithium cell - A primary cell having an anode comprising lithium and a cathode comprising iron disulfide (FeS | 01-22-2009 |
Zhiwei Jiang, Stow, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090226395 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential - The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues. | 09-10-2009 |
| 20100151037 | METHOD FOR THE PREPARATION OF NANOPARTICLES CONTAINING A POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE COMPOUND - The present application relates to a method for preparing nanoparticles containing a poorly water-soluble pharmaceutically acceptable compound and compositions containing such nanoparticulates. | 06-17-2010 |
| 20110112180 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS - The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds. | 05-12-2011 |
| 20120252763 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS - The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds. | 10-04-2012 |
Zhong Jiang, Northborough, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080242606 | Use of IMP3 as a Prognostic Marker for Cancer - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 10-02-2008 |
| 20100211066 | Use of IMP3 as a Prognostic Marker for Cancer - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 08-19-2010 |
| 20110034398 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 02-10-2011 |